The Wall Street Journal
@wsj·6.6M subscribers·28.9K videos
The Controversial Pink Pill That Boosts Female Sexual Desire | WSJ
Posted
August 19, 2015
Views
1,521,738
Likes
3,698
Comments
110
Engagement
August 19, 2015
1,521,738
3,698
110
0.25%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
2:04Now PlayingThe U.S. Food and Drug Administration has approved Flibanserin, the first prescription drug to boost sexual drive in women. Developed by a small company in North Carolina called Sprout Pharmaceuticals, Addyi is marketed as a drug for women with hypoactive sex drive disorder that has been rejected twice before.
WSJ’s Mark Kelly reports on the potential side effects and covers the controversy behind the pink pill.
#FDA #Drug #WSJ
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
